Anixa Biosciences, Inc.
ANIX
Rank in Stocks
#19296
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to... Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Share Price
$3.16
Last synced: 2026-11-09
Market Cap
$109.85M
Change (1 day)
-0.47%
Change (1 year)
-28.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Anixa Biosciences, Inc. (ANIX)
Category
Healthcare
EPS for Anixa Biosciences, Inc. (ANIX)
EPS as of July 2026 TTM: $-0.30
According to Anixa Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-0.30. At the end of 2025 the company had an EPS of $-0.34, an increase over its 2024 EPS of $-0.39.
EPS history for Anixa Biosciences, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.30 | -11.76% |
| 2025 | $-0.34 | -12.82% |
| 2024 | $-0.39 | 21.88% |
| 2023 | $-0.32 | -28.89% |
| 2022 | $-0.45 | 0.00% |
| 2021 | $-0.45 | -2.17% |
| 2020 | $-0.46 | -24.59% |
| 2019 | $-0.61 | -22.78% |
| 2018 | $-0.79 | 92.68% |
| 2017 | $-0.41 | -28.07% |
| 2016 | $-0.57 | 307.14% |
| 2015 | $-0.14 | -86.00% |
| 2014 | $-1.00 | -14.53% |
| 2013 | $-1.17 | 120.75% |
| 2012 | $-0.53 | -47.52% |
| 2011 | $-1.01 | 27.85% |
| 2010 | $-0.79 | -70.74% |
| 2009 | $-2.70 | 164.71% |
| 2008 | $-1.02 | -15.00% |
| 2007 | $-1.20 | -33.70% |
| 2006 | $-1.81 | 58.77% |
| 2005 | $-1.14 | 23.91% |
| 2004 | $-0.92 | -2.13% |
| 2003 | $-0.94 | -14.55% |
| 2002 | $-1.10 | -12.70% |
| 2001 | $-1.26 | -30.39% |
| 2000 | $-1.81 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -5,320.00% |
US
|
|
| $-7.07 | 2,256.67% |
US
|
|
| $-5.29 | 1,663.33% |
AU
|
|
| $12.88 | -4,393.37% |
BE
|
|
| $21.56 | -7,286.67% |
NL
|
Questions about Anixa Biosciences, Inc.'s earnings per share (EPS)
What is Anixa Biosciences, Inc.'s earnings per share (EPS)?
Anixa Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-0.30, as of Jul 2026.
What was Anixa Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Anixa Biosciences, Inc.'s earnings per share (EPS) was $-0.34, compared with $-0.39 in 2024.
How has Anixa Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Anixa Biosciences, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.32) and lowest in 2020 ($-0.46).
How does Anixa Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Anixa Biosciences, Inc.'s earnings per share (EPS) ($-0.30) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.